POC Sample Clauses

POC. POC" shall mean point-of-care applications of the Cholesterol 1,2,3 System applied under the direction or supervision of medical practitioners and clinicians.
Sample 1Sample 2
AutoNDA by SimpleDocs
POC. POC (a) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation; (b) is duly qualified as a foreign corporation and in good standing under the laws of each jurisdiction where its ownership or lease of property or the conduct of its business requires such qualification; (c) has all necessary power pursuant to proper authorization to enable it to enter into the Credit Documents lo which it is a party; (d) is duly qualified to do business in and is in good standing under the laws of each other jurisdiction where the failure to do so could have a Material Adverse Effect; and (c) has the corporate or other necessary power and authority, and the legal right, to conduct the business in which it is currently engaged.
Sample 1
POC. Upon award of a new Task Order based upon the TTD proposal, the Contractor shall perform the TTD at the direction of the COR. If at any time during performance of the TTD, the contractor anticipates exceeding the TTD estimate (Budget NTE), the Contractor shall notify the COR and generate a TTD proposal revision as directed by the COR. The Contractor shall also notify the COR via electronic mail and generate a TTD proposal revision when the TTD is complete with a balance of funds remaining (as applicable). The Contractor will use the current rates for estimating costs for TTDs, but will be reimbursed for those costs in accordance with 52.216-7, Allowable Cost and Payment, incorporated into this contract. If at any time during performance of the TTDs, the Contractor anticipates exceeding funding obligated on the CLIN 0004, the Contractor shall provide notice to the Contracting Officer and COR in accordance with FAR clauses 52.232-20, Limitation of Cost, or 52.232-22, Limitation of Funds. The issuance of TTDs exceeding available funding does not authorize the Contractor to exceed the amount of Government funding obligated to CLIN 0004 or extend the period of performance for CLIN 0004. (End of Clause) 5652.209-9003 5652.209-9003 Use of Contractor Support/Advisory Personnel (2015) Section H (Revised August 2015) The contractor’s attention is directed to the fact that USSOCOM contracts for various IT, business, acquisition, technical, and staff support services, some of which require support contractor access to proprietary information submitted by other contractors during administration of this contract. Execution of this contract constitutes approval to release the contract, contractor proposals, other contractor information, or proprietary data obtained during contract administration to Government Support Contractors who require access and have signed Non-Disclosure and Rules of Conduct/Conflict of Interest Statements.
Sample 1
POC. The one installation representative from DoD responsible for developing the JEP in coordination with the State POC or State Alternate POC. The Step 2 POC is the representative responsible for locking the JEP.
Sample 1
POC. The Borrower shall, not later than October 15, 1996, establish and thereafter maintain until completion of the Project a Project Oversight Committee ("POC") within each province of the Project Area with membership and terms of reference satisfactory to the Association. The POC shall be responsible for: (i) reviewing and approving the annual provincial work plans and related budgets and progress reports in respect of Project implementation, prior to their submission to the PSU for Project-wide consolidation and final approval by the PSC; (ii) coordinating between the various provincial governmental agencies involved in Project implementation; and (iii) reporting, through the PSC, on issues which might affect or otherwise interfere with the successful implementation of the Project and the achievement of its objectives in the province concerned.
Sample 1
POC. POC is a limited liability company duly formed, validly existing and in good standing under the laws of the State of Colorado. POC was formed on December 12, 2005 as a Colorado limited liability company and as of the date of this Agreement does not own and has never owned any assets and is not subject to any liabilities. The Company and POC have satisfied all conditions and obtained all consents and approvals necessary to enable (i) the transfer and assignment of the PGR LLC Interests by the Company to POC, (ii) POC to act as the Operator under the JOA, and (iii) the redemption of the PGR LLC Interests by POC in consideration for the Direct Assignment, other than as provided in Schedule 3.8, which shall set forth all such consents and approvals obtained or to be obtained, and the transfer of such PGR LLC Interests and the redemption and Direct Assignment will be effected in compliance with applicable law and the terms of all applicable agreements.
Sample 1
POC 
Sample 1
AutoNDA by SimpleDocs

Related to POC

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Feasibility Study 4.3.1 The Feasibility Study shall identify any potential adverse system impacts that would result from the interconnection of the Generating Facility.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

Time is Money Join Law Insider Premium to draft better contracts faster.